Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both...
-
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter...
-
Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors
-
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today...